BioHarvest Sciences Inc. (CSE:BHSC, OTC:CNVCF) has highlighted the unique composition of one of its Bio CELLicitation-based cannabis products grown from a CBD Hemp plant that the company said has major medical and commercial implications.
The company said the analysis of its composition was derived using industry-standard HPLC measurements conducted by an independent third-party analytical laboratory which is ISO17025 cGMP accredited and certified by the Israeli Ministry of Health.
BioHarvest said its composition demonstrated unprecedented cannabinoid tuning and elicitation capabilities, a 12 times increase when compared to the original plant, using its proprietary Bio-Plant CELLicitation platform technology.
READ: BioHarvest Sciences closes first tranche of previously reported oversubscribed private placing for around C$6.9 million
The company’s composition contains high amounts of minor cannabinoids such as THCV (2.5%) and CBDV (4.4%), providing unique medical and commercial benefits. A full breakdown of BioHarvest’s unique composition compared to the source hemp plant flower can be found here.
BioHarvest CEO Ilan Sobel said this rich cannabinoid composition was unprecedented, and its wealth of features open the door for many lucrative commercial and medical applications.
"The ability to produce unique cannabis and hemp-based compositions gives us tremendous flexibility to decide which markets to pursue, what would be the optimal product offerings and partnerships,” Sobel said.
“In addition, the high level of cannabinoids, combined with our unique cost advantage opens the door for the production of distillates and isolates of specific cannabinoids resulting in multiple levers to optimize revenue and profitability from this vertical".
Center for Integrated Medicine at the University of Maryland, School of Medicine director Dr Christopher D'Adamo added: “These achievements by BioHarvest in naturally eliciting important minor cannabinoids to significant biologically active levels, combined with high levels of major cannabinoids, all produced with a high level of consistency represent a major breakthrough towards the development of efficient cannabis-based botanical drugs.”
BioHarvest is a Canadian biotech firm that has developed a patented bio-cell growth platform technology capable of growing the active and beneficial ingredients in fruit and plants, at an industrial scale, without the need to grow the plant itself.
Contact the author at emily.jarvie@proactiveinvestors.com
Follow her on Twitter @emilyjjarvie